文献速递复苏、休克与脓毒症创伤与烧伤

肌注特利加压素单药治疗用于未控制创伤性失血性休克早期管理的初步研究

INTRAMUSCULAR TERLIPRESSIN AS MONOTHERAPY FOR EARLY MANAGEMENT OF UNCONTROLLED TRAUMATIC HEMORRHAGIC SHOCK: A PRELIMINARY STUDY.
PubMed 文献 · Shock · 2025-01-01
一句话结论大鼠未控制创伤性失血性休克模型中,肌注特利加压素(5 μg/100 g)可改善早期血流动力学及肌肉、肠道、肾脏病理损伤,但多器官功能标志物无显著差异。

该研究在成年雄性 Sprague-Dawley 大鼠未控制创伤性失血性休克(UTHS)模型中,比较假手术、休克、肌注特利加压素(5 μg/100 g)、静注特利加压素(10 μg/100 g)、生理盐水(1.5 mL/100 g)和去甲肾上腺素(0.3 μg/kg/min)六组干预 60 分钟的效果。肌注特利加压素后 8 分钟平均动脉压开始升高,40 分钟和 70 分钟时全身灌注压分别高于生理盐水组和去甲肾上腺素组;微循环功能障碍相关生物标志物改善,肌肉、肠道、肾脏病理损伤评分改善。但多器官功能标志物组间无显著差异。作者认为肌注特利加压素改善了 UTHS 后早期血流动力学和多器官病理损伤,未来需研究其保护作用的分子机制。

要点

  • 大鼠 UTHS 模型中,肌注特利加压素 5 μg/100 g 后 8 分钟平均动脉压开始升高。
  • 肌注特利加压素组全身灌注压在 40 分钟时高于生理盐水组、70 分钟时高于去甲肾上腺素组。
  • 与生理盐水组和去甲肾上腺素组相比,肌注特利加压素组微循环功能障碍相关生物标志物改善。
  • 多器官功能标志物组间无显著差异,但肌注特利加压素改善肌肉、肠道、肾脏病理损伤评分。
  • 作者认为肌注特利加压素改善 UTHS 后早期血流动力学和多器官病理损伤,未来需阐明其分子机制。

适用人群与场景

  • 成年雄性 Sprague-Dawley 大鼠,每组 8 只,共六组;UTHS 模型经中线剖腹、股动脉出血和断尾制作,手术止血后复苏大鼠接受 1 小时失血回输。

处置流程与药物剂量

  • 肌注特利加压素组:特利加压素 5 μg/100 g,肌内注射,单次,观察 60 分钟。
  • 静注特利加压素组:特利加压素 10 μg/100 g,静脉注射,单次,观察 60 分钟。
  • 生理盐水组:生理盐水 1.5 mL/100 g,观察 60 分钟。
  • 去甲肾上腺素组:去甲肾上腺素 0.3 μg/kg/min,观察 60 分钟。

研究设计与关键结果

  • 研究类型:动物实验(大鼠 UTHS 模型),每组 8 只,共六组(假手术、休克、肌注特利加压素、静注特利加压素、生理盐水、去甲肾上腺素),干预观察 60 分钟。
  • 肌注特利加压素后 8 分钟平均动脉压开始升高。
  • 全身灌注压:肌注特利加压素组在 40 分钟时高于生理盐水组,在 70 分钟时高于去甲肾上腺素组。
  • 与生理盐水组和去甲肾上腺素组相比,肌注特利加压素组微循环功能障碍相关生物标志物改善。
  • 多器官功能标志物组间无显著差异;肌注特利加压素组肌肉、肠道、肾脏病理损伤评分改善。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠 UTHS 模型)。
  • 作者指出未来需进一步研究以阐明该治疗保护作用的分子机制。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在 UTHS 大鼠模型中肌注特利加压素改善了早期血流动力学和多器官病理损伤;该结果来自动物实验,作者提出未来需阐明其保护作用的分子机制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Monotherapy using a single-dose vasopressor to maintain essential organ perfusion could be a viable alternative to restrictive fluid resuscitation in uncontrolled traumatic hemorrhagic shock (UTHS). This study evaluated the impact of intramuscular terlipressin on hemodynamics and organ injuries in UTHS. Adult male Sprague-Dawley rats, with eight rats in each group, were assigned to six distinct groups. Immediately after randomization, the rats in each group were exposed or not exposed to specific interventions over a 60-min period, as follows: sham, shock, intramuscular terlipressin (5 μg/100 g), intravenous terlipressin (10 μg/100 g), normal saline (1.5 mL/100 g), and norepinephrine (0.3 μg/kg/min). The UTHS model was created by midline laparotomy, femoral artery bleeding, and tail amputation. After surgical hemostasis, resuscitated rats had a 1-h infusion of lost blood. Invasive blood pressure comparations and organ injury assessments were performed. Mean arterial pressure was increased starting 8 min after intramuscular injection of terlipressin. The systemic perfusion pressure from intramuscular terlipressin was notably higher than that from normal saline and norepinephrine after 40 and 70 min, respectively. In comparison with rats treated with normal saline and norepinephrine, those receiving intramuscular terlipressin demonstrated improvements in biomarkers related to microcirculation dysfunction. Although there were no significant differences in multiorgan function markers among the groups, intramuscular terlipressin led to improvements in the pathological injury scores of the muscle, intestine, and kidney. Collectively, intramuscular administration of terlipressin improved early hemodynamics and multiorgan pathological injuries after UTHS. Future investigations are warranted to elucidate the molecular mechanisms underpinning the protective effects of this treatment.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Jiang S, Ma X, Rao T, et al. INTRAMUSCULAR TERLIPRESSIN AS MONOTHERAPY FOR EARLY MANAGEMENT OF UNCONTROLLED TRAUMATIC HEMORRHAGIC SHOCK: A PRELIMINARY STUDY. Shock. 2025. PMID: 40139987. doi:10.1097/SHK.0000000000002594

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。